Robert Wirthlin, MD
Enriched profileRetina specialist (vitreoretinal ophthalmologist) · Spokane Eye Clinic
Robert Wirthlin is Retina specialist (vitreoretinal ophthalmologist) at Spokane Eye Clinic. ClinicalTrials.gov lists 1 registered study with this person as an investigator.
Data verified 17 Oct 2026
Overview
Updated 18 Oct 2026
Robert Wirthlin, M.D., is Retina specialist (vitreoretinal ophthalmologist) at Spokane Eye Clinic (joined July 2006). The public record shows 25 publications with 783 citations (h-index 11), centered on Diabetic Retinopathy / DME, Macular Edema. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 12 companies.
- Top research focus: Diabetic Retinopathy / DME
- 1 registered trials on ClinicalTrials.gov
- Open Payments reporting from 12 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:
- A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)
Sponsor: Johns Hopkins University
Industry payments
Updated 18 Oct 2026
12 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Regeneron Healthcare Solutions, Inc.Program year202523 payments$33,065openpaymentsdata.cms.gov ↗
- Astellas Pharma US IncProgram year20253 payments
- ABBVIE INC.Program year20256 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
92%Antineovascularisation agents90.5%Faricimab-svoa100%Part B, office-administered≥160 patientsVascular Endothelial Growth Factor Inhibitor0.9%Ranibizumab100%Part B, office-administered≥20 patients+ 7 more classes in this area
Cancer & immunology
7.7%Complement Inhibitor4.8%Pegcetacoplan100%Part B, office-administered≥38 patientsVascular Endothelial Growth Factor Inhibitor2.8%Aflibercept100%Part B, office-administered≥163 patientsMetabolism & gastrointestinal
0.2%Anticholinergic0.2%Atropine Sulfate100%Part D≥85 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Port-Delivery-Plattform mit Ranibizumab (PDS) bei Augen mit hoher Injektionslast: Interimsanalyse der Belvedere-Studie bei Patienten mit nAMD
German Medical Science (German Research Foundation)
2026
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- Board-certified ophthalmologist (vitreoretinal diseases); Inteflex integrated program
University of Michigan Medical School; ophthalmology residency, Bascom Palmer Eye Institute/University of Miami …
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →kerbsidehealth.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Joel Schuman, MD
Wills Eye Hospital